GSK plc Stock

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Market Closed - London S.E. 11:35:01 2024-04-12 EDT 5-day change 1st Jan Change
1,644 GBX +0.89% Intraday chart for GSK plc +0.86% +13.33%

Financials

Sales 2024 * 31.47B 39.18B 53.97B Sales 2025 * 33.39B 41.57B 57.26B Capitalization 67.15B 83.61B 115B
Net income 2024 * 5.64B 7.02B 9.67B Net income 2025 * 6.25B 7.78B 10.72B EV / Sales 2024 * 2.53 x
Net Debt 2024 * 12.32B 15.34B 21.13B Net Debt 2025 * 9.18B 11.43B 15.75B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
12 x
P/E ratio 2025 *
10.6 x
Employees 70,212
Yield 2024 *
3.72%
Yield 2025 *
4.01%
Free-Float 92.58%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.89%
1 week+0.86%
Current month-3.81%
1 month-2.47%
3 months+4.48%
6 months+8.14%
Current year+13.33%
More quotes
1 week
1 605.50
Extreme 1605.5
1 651.75
1 month
1 593.50
Extreme 1593.5
1 713.00
Current year
1 453.20
Extreme 1453.2
1 719.80
1 year
1 302.60
Extreme 1302.6
1 719.80
3 years
1 280.92
Extreme 1280.92
3 408.16
5 years
1 280.92
Extreme 1280.92
3 408.16
10 years
1 280.92
Extreme 1280.92
3 408.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 10-04-30
Director of Finance/CFO 62 23-04-30
Compliance Officer - 95-07-31
Members of the board TitleAgeSince
Director of Finance/CFO 62 23-04-30
Chairman 66 19-08-31
Director/Board Member 65 14-12-31
More insiders
Date Price Change Volume
24-04-12 1,643 +0.89% 6,715,126
24-04-11 1,629 +0.49% 8,322,644
24-04-10 1,621 +0.31% 6,449,551
24-04-09 1,616 -0.25% 7,799,268
24-04-08 1,620 -0.58% 4,647,859

Delayed Quote London S.E., April 12, 2024 at 11:35 am

More quotes
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
16.44 GBP
Average target price
20 GBP
Spread / Average Target
+21.69%
Consensus